NCT04057703View on ClinicalTrials.gov

Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia.

CompletedOBSERVATIONAL

Enrollment

454

Participants

Timeline

Start Date

January 18, 2016

Primary Completion Date

December 4, 2016

Study Completion Date

December 4, 2016

Conditions

Immune Thrombocytopenic PurpuraAutoimmune Hemolytic AnemiaEvan SyndromeImmunotherapy

All Listed Sponsors

lead

University Hospital, Bordeaux

OTHER

NCT04057703 - Balance Benefit / Risk of Immunomodulatory Treatments at the Child and Adolescent for Autoimmune Cytopenia. | Biotech Hunter | Biotech Hunter